
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NPT2 CRISPR/Cas9 KO Plasmid (h) | sc-402216 | 20 µg | $397.00 |
SLC34A1 encodes the human sodium-dependent phosphate transport protein 2A (NPT2), an apical membrane cotransporter that mediates electrogenic uptake of inorganic phosphate coupled to Na+ gradients in epithelial cells. NPT2 is a key determinant of phosphate homeostasis and participates in renal proximal tubule reabsorption pathways that intersect with vitamin D metabolism, parathyroid hormone signaling, and FGF23-regulated phosphate handling. Altered SLC34A1 function has been associated with disorders of phosphate balance, including phenotypes linked to nephrolithiasis, hypophosphatemia, and defects in mineralization, making it relevant for studying epithelial transport regulation and metabolic signaling. At the cellular level, SLC34A1 perturbation can be used to interrogate membrane trafficking, transporter kinetics, and phosphate-dependent control of bioenergetics and biomineral metabolism.
NPT2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SLC34A1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SLC34A1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SLC34A1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish NPT2 protein expression.
This CRISPR knockout system enables efficient generation of SLC34A1-deficient cell models for investigation of NPT2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.